Avitar to acquire Genua:
This article was originally published in Clinica
Avitar is expanding its presence in the rapid diagnostic test market with the planned stock purchase of Genua, a privately-held diagnostics company. Genua developed its Rapid Saliva Kits for HIV and hepatitis which include a custom-designed form of Avitar's Accu-sorb saliva collection devices. Genua recently revealed positive results of correlation studies for these tests, conducted at the Nassau County Medical Center, East Meadow, New York. Furthermore, Genua owns distribution rights to drugs-of-abuse and pregnancy tests. Avitar is a manufacturer of a range of healthcare products including Hydrasorbd, a line of polyurethane dressings.
You may also be interested in...
The director of adult immunizations at Johns Hopkins International Vaccine Access Center talks to Scrip about undertaking a massive COVID-19 vaccination effort in the US.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.